Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Mind & Matter

Mind & Matter artwork

Your Ancestry Changes How Your Body Handles Omega-3 and Omega-6 Fats | Floyd Chilton | 294

May 22, 20261 hr 52 minAudio
ShareXLinkedInFacebookWhatsAppEmail

Send us Fan Mail Human genetic variation in dietary fat metabolism and its implications for health & disease. TOPICS DISCUSSED: Linoleic Acid Rise: Linoleic acid now comprises 6-8% or more of energy in Western diets. Metabolic Pathways: Omega-6 linoleic acid converts to arachidonic acid and pro-inflammatory oxylipins; omega-3 ALA converts via shared enzymes to EPA/DHA with anti-inflammatory effects. FADS Genetic Variants: Ancestry-linked haplotypes in the FADS cluster create large “pipe” size differences, altering fatty acid by up to 40% between ancestral and derived versions. Population Differences: African ancestry populations often have high-conversion “big pipe” genotypes; Indigenous American ancestry populations have low-conversion “small pipe” genotypes; European ancestry comes with a mix of both. Omega-3 Deficiency: High linoleic intake suppresses EPA production, especially in small-pipe populations, contributing to hypertriglyceridemia and fatty liver in Mexican cohorts. Clinical Evidence: Reanalysis of VITAL trial showed 83% reduction in myocardial infarction with omega-3 supplementation in African Americans; Mexican data link low EPA to unique diabetes forms. Methodological Issues: Compositional data (from GC-FID measurements) versus absolute concentration measurements can flip relationships between linoleic acid and key biomarkers. ABOUT THE GUEST: Floyd Chilton PhD is Professor and Director of the Center for Precision Nutrition and Wellness at the University of Arizona. His research focuses on functional genomics, fatty acid metabolism, and precision nutrition, particularly how genetic ancestry influences responses to dietary fats. RELATED EPISODE: M&M 291: Omega Polyunsaturated Fats & Inflammation | Philip Calder Support the show Support my work: Good Chemistry: Personalized, science-based health consulting. Work with Dr. Nick Jikomes directly. Affiliate Partners: Visit this link to see my affiliate partners and get discounts codes for products & services to support health. For all the ways you can support my efforts.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

Nick JikomesHey everyone, a great way to support my efforts is to visit my support page at mindandmatter.substack.com. A link to that page is in the episode description or you can search for it on the Substack page itself. The support page has an up-to-date list of my affiliate partners. These are companies I work with and if you buy those products through those links or using the discount codes provided, those will get you a great deal on a variety of products related to optimizing physical, metabolic, or mental health and vitality. These are all products I use myself, and some of them are directly related to podcast episodes or formulated by Mind & Matter guests. For example, there's a great product called Keto Citra, formulated by a kidney biologist who was on episode number 186. It contains the ketone body BHB together with several minerals in a precise ratio formulated with kidney health in mind. There are also links to products like physical technology devices to track your metabolic health, digital applications to help you find and learn about food and consumer products, and more.

Nick JikomesOne product I use every day is the AquaTrue water filter. I recommend this to everyone because it gets everything out of your drinking water, heavy metals, microbes, endocrine disruptors, microplastics, you name it. Other charcoal or gravity-based filters that a lot of people use don't get everything out, they just get some of the stuff out. So I really like the AquaTrue product. You can look for a link to my affiliate partners on my support page or directly in the episode description to this episode, or you can go to mindandmatter.substack.com to find it there. Ski Chilton, thank you very much for joining me. I've been looking forward to chatting with you in particular on this subject for a while. Do you want to just start off by telling everyone a little bit about who you are and what your background is as a scientist?

Floyd "Ski" ChiltonSure. My name is Ski Chilton, as you've said, Nick. I got my PhD at Wake Forest in biochemistry. I did my postdoc at the University of Colorado with a guy who was part of the Nobel Prize winning team that discovered leukotrienes, oxylipins, prostaglandins. His name was Robert Murphy. I was recruited to Johns Hopkins professor there for six years. Then came back home to North Carolina, professor, head of molecular and translational medicine at Wake Forest for another 15 years or so. And most recently, I'm old, and most recently, I spent the last eight years at the University of Arizona.

Floyd "Ski" Chiltonbuilding a Center for Precision Nutrition and Wellness. I'm also a visiting professor of Functional Genomics at Tecna Monterey. They have a family of distinguished faculty, and I play a role at Tec de Monterrey. Again, Tec de Monterrey, 30 campuses throughout Latin America, primarily in Mexico.

Floyd "Ski" ChiltonAnd again, the area is functional genomics.

Nick JikomesSo we're going to talk today about dietary fats and their metabolites and human genetics and human metabolic variation, how we vary in terms of how we process and metabolize some of the components of the foods that we eat. A lot of this stuff is ground I've covered in quite a bit of detail. It's an area of interest of mine. I've written about it. I've had different guests on, including recent guests. And as I think we'll come to, there's definitely a variety of viewpoints when it comes to dietary polyunsaturated fats, ranging from, well, we'll talk about it, but there's a wide range of viewpoints on this, both in the scientific community and in the public. And we'll get into all that. I don't want to spend too much time on the bare bones basics.

Nick JikomesThis is going to be more of a deep dive episode and not a basic episode for the completely uninitiated. Nonetheless, let's do a little bit of background to start. What are dietary polyunsaturated fatty acids and what does it mean when people describe them as essential nutrients?

Floyd "Ski" ChiltonWell, essential nutrients means we can't make them, so we must ingest them. And I classify them into two categories. There are perhaps three or four categories. There's omega-6 polyunsaturated fatty acids, and there are omega-3 polyunsaturated fatty acids. And the primary dietary fatty acids are an omega-6 known as linoleic acid. It's currently 6% to 8% of our energy. Probably nothing in the modern Western diet changed as much as an increase in consumption of linoleic acid, that omega-6 fatty acid. Now, linoleic acid, again, is converted, and I won't go through the enzymes or the genetics, but it's converted to arachidonic acid.

Floyd "Ski" ChiltonI classify those as highly unsaturated fatty acids. So it's converted to arachidonic acid. Again, we'll get into this, but it's converted differently based on ancestry and profoundly differently to arachidonic acid. And then arachidonic acid gives rise to probably several hundred, at least 150 pro-inflammatory, prothrombotic oxylipins and there are some oxylipins from arachidonate that have opposite effects, but by far, by far, the majority of those oxylipins from arachidonic acid are pro-inflammatory or prothrombotic.

Floyd "Ski" ChiltonAnd if you mess up the balance there, as we saw with the COX-2 inhibitors, you can get into some really cardiovascular problems. So on the other side are omega-3 fatty acids. And the primary dietary omega-3 fatty acid is alpha-linolenic acid. Alpha-linolenic acid is converted by the same pathway as linoleic acid, the omega-6, to eicosapentaenoic acid.

Floyd "Ski" ChiltonThree steps down the way, eicosapentaenoic acid, EPA, sits right where arachidonic acid sits. So they are right in the same step, an omega-6 on one side, an omega-3 on the other. EPA is then converted to DPA. And then DHA, again, 60% of our brain mass is fat. And 60% of neuronal membranes are DHA. So DHA plays a critical role. in brain development and brain function. EPA plays more of an anti-inflammatory, anti-thrombotic, pro-resolving role.

Floyd "Ski" ChiltonSo, it's kind of a, not to sound too out there, but it's a kind of a yin-yang pathway. You've got the omega-6s that are driving immunity, innate immunity, and inflammation, thrombosis. You've got the omega-3 side that are anti-inflammatory, anti-thrombotic, pro-resolving, And so each side of the pathway must be balanced.

Nick JikomesSo these are essential fatty acids. We can't make them ourselves. Human cells can't make them from scratch. So we have to eat them in order to obtain them. They're processed by the same enzymes. So the omega-3s that we eat and the omega-6s that we eat will be converted into other things that we'll talk about, some of the examples we'll talk about, but they're processed by the same enzymes. So there's kind of a balance that's needed in terms of, A, they've got different effects. They can be pro-thrombotic, pro-inflammatory on one side, the omega-6 side, and they can be anti-inflammatory, anti-thrombotic on the other side, the omega-3 side.

Nick JikomesBut because they're functionally different and because they're processed by the same enzymes, an imbalance between those two classes can cause issues. That's the basic idea, right?

Floyd "Ski" ChiltonThat's the basic idea.

Nick JikomesOkay. Now, there's a variety of things that these fatty dietary fatty acids can be turned into. And I want to give people sort of a general view of what the space of things is that can come from these dietary fats. And then maybe we'll do a somewhat deeper dive on one or two or three classes that you know well, and that are a little bit more well studied. But I want to first go back to something you said, you said that linoleic acid, this is the primary omega six in the diet that comes from things like seed oils and highly processed foods. You said that's now, by some estimates, 6% to 8%. Some estimates even put it a little bit higher than that, of total calories today. Meaning, if I'm hearing this correctly, almost 1 in 10 calories, units of energy that we consume today, the average American at least, are coming from one molecule, linoleic acid.

Nick JikomesIs that true?

Floyd "Ski" ChiltonThat's exactly true. I mean, this began in 1961. It began as a recommendation from the American Heart Association. The studies showed that linoleic acid reduced cholesterol and cholesterol esters, and based on those initial trials, the American Heart Association recommended replacing saturated fatty acids with polyunsaturated fatty acids.

Floyd "Ski" ChiltonNow, it didn't discern between omega-6 and omega-3, but the omega-6s that were available in the industry or the polyunsaturated fatty acids that were available in the industry were dramatically linoleic acid containing, the biggest one being soybean oil, which is currently about 8% to 9% energy that we take in. And soybean oil is, I think, around, not I think, I know around, 54% linoleic acid. So all of a sudden the cooking oils, the seed oils that we're producing, we're eating very high amounts of linoleic acid and that took energy from a 2 to 1 ratio of linoleic acid to alpha linoleic acid to, depending on who's looking, but somewhere between 10 and 15 to 1 linoleic acid to alpha linoleic acid, the omega 6 to the omega 3.

Nick JikomesSo, If we go back many decades, and for most of human history, the intake of Omega-6s and Omega-3s was approximately balanced, 1 to 1, 2 to 1, maybe a little bit more in favor of the Omega-6s. Around the mid-20th century, for reasons we don't necessarily need to get into here, but it became the mainstream view from the American Heart Association and other institutions that people should be eating more polyunsaturated fats because they lower cholesterol, and that was supposed to be the key to preventing heart disease. They did not distinguish between the omega-6s and the omega-3s.

Nick Jikomesat the time at least. And that's a big distinction that needs to be made because these things have such different effects in the body, but they didn't make that distinction. So dietary polyunsaturated fats were recommended wholesale. The most common one came from the crop that we had the most of, which was soybeans. So soybean oil and other seed oils went into processed foods. They became the vegetable oils that people use for cooking. They replaced things like butter and other animal sources of fat. And so people went from maybe a two-to-one omega-6-to-3 ratio to a five-to-one, 10-to-one, maybe even 20-to-one ratio.

Nick JikomesI've had people send me their omega-quant, omega-6-3 tests, and they're at 15-to-one, 20-to-one, even 30-to-one I've seen. And so the moral of the story is perhaps more than any other change in the macronutrient composition in the modern industrial diet, maybe the biggest one probably has been the increase in omega-6 intake predominantly from linoleic acid.

Floyd "Ski" ChiltonYes, I think that's factual. I think you know this subject quite well. You speak it quite well, but I think everything you've said is factual.

Nick JikomesSo I wanna come now to these oxylipins, some of the downstream, some of the stuff our bodies make from these dietary fats. And I wanna give people sort of a survey of the things that get made out of omega-6 fatty acids like linoleic acid to start with. So you mentioned earlier, we eat linoleic acid, we eat the seed oils, we're putting linoleic acid into our bodies. For a lot of us, that's almost one in 10 of the energy content of the diet we're eating for the average American. What does that linoleic acid turn into after it goes to arachidonic acid? What types of molecules and what do those things do?

Floyd "Ski" ChiltonWell, as I said, I was so fortunate to be in the lab of Bob Murphy. And Bob Murphy discovered leukotriene C4, D4, and E4. That was slow-reacting substance of anaphylaxis. So he discovered that shortly before I got to his lab. So again, that was a pulmonary And again, I'm only talking about one of 150, but LTC4, D4, and E4 was slow-reacting substance of anaphylaxis that played a critical role in asthma and respiratory diseases. During the same time, LTB4 was discovered, potent chemotact, Chemotaxis brought white cells into sites of produced inflammation. Then the prostaglandins, leukotriene, stormboxanes, very prothrombotic again. platelet aggregation, critical role in cardiovascular disease, prostacyclin kind of a balance among the arachidonates in the other direction.

Floyd "Ski" ChiltonYou know, I've just explained four or five, and kind of that's what we knew up until probably 15 years ago. But then the field exploded. We now know there's 150 to 200. My lab typically measures about 65 of these. It's kind of impossible. They're produced by lipoxygenase pathway, cyclooxygenase pathway, P450 pathways. So they're produced by several different enzymatic mechanisms. They're typically oxygenated at different locations on the molecule.

Floyd "Ski" ChiltonAnd when it comes to arachidonate, again, many of us know of some that are anti-inflammatory or are not thrombotic, but by far, by far, the vast majority are very pro-inflammatory or thrombotic or vasoconstrictive or smooth muscle constrictive and play a role. They play a critical role in innate immunity and they would have for our early ancestors. It was critical to maintain innate immunity. So they would have played a critical role.

Nick JikomesRight, because if you're living out in the bush hundreds or thousands of years ago, you're going to get exposed to lots of pathogens. Infectious disease was a major killer, potentially the major killer of humans for most of our evolutionary history. So obviously, you need to supply the immune system with the firepower it needs. You need to be able to generate inflammation to handle infections, to regenerate and clear out dead tissue after injury. You need to be able to induce thrombosis and vasoconstriction. When you say those things, we're basically higher blood pressure, thicker blood, clotting, things like that. If you think about a hunter-gatherer getting infected, getting injured, these are the things that helped us deal with those problems, right?

Floyd "Ski" ChiltonAbsolutely. They were critical.

Nick JikomesAnd so what else So let's back up for a sec. A linoleic acid, we eat it, it's an omega-6, it turns into arachidonic acid, but there's not just one linear path here. There's a whole family of enzymes. Each one can process these omega-6s in different directions. So people might imagine in their mind sort of a branching tree structure. The omega-6s can go down any one of these paths depending on context, depending on the cell that they're in, and depending on genetics as we'll come to. So there's lots of possibilities. Lots of molecules that do different things can be made from these omega-6s.

Floyd "Ski" ChiltonWell, certainly from arachidonic acid. But there are oxylipins that come from linoleic acid as well. There's a great deal of concern that linoleic acid is in, again, your fast food fryer and at a very high temperature. And the oxidants being produced from those could have detrimental effects and have been shown to have detrimental effects. So yes, the linoleic acid down that pathway make a few oxylipins. When you get to arachidonic acid, you make a boatload.

Nick JikomesYeah. And so you mentioned, you know, there's lots of things that arachidonic acid can be turned into. Some might be prothrombotic or anti-thrombotic. Some might be pro-inflammatory, anti-inflammatory. But on balance, most of these things on the omega-6 arachidonic acid side are prothrombotic and pro-inflammatory. Can you give us a little bit more there? Because I hear a lot and I've seen a lot in the literature, including from very famous scientists who've written about the subject, they say, no, actually it's a myth that omega-6s are pro-inflammatory. They're actually non-inflammatory or even anti-inflammatory.

Nick JikomesWhat do you make of that claim and why is there a discrepancy between what some people say in terms of the relationship between these omega-6s and inflammation?

Floyd "Ski" ChiltonYou're stating the established narrative, and I've seen who has been on your podcast, and they're good friends of mine, and I respect them deeply. The established narrative is, and we can go into why I believe the narrative is not correct, but the established narrative is And there are several reasons I believe it's not correct. But the established narrative is there is no evidence that linoleic acid is detrimental for you. There's little evidence that it increases arachidonate.

Floyd "Ski" ChiltonAnd so it has by prospective cohort studies and huge, huge meta-analyses, has been shown to be cardioprotective, even anti-inflammatory, reduce all-cause mortality. So, these huge, huge prospective studies by people that I I've known for 30 years, care deeply about, really have the highest scientific respect for. The established narrative is that that is good for you, that that's going to have health benefits.

Nick JikomesOne of the exercises I've done over the last roughly three years as I've gotten interested in this field, is that I've actually gone in and I've read these meta-analyses, but even more important than that, I've actually gone in and read the underlying clinical trials that they cite in the systematic reviews and the meta-analyses, and I was very disturbed by what I found. Very often, the clinical trials cited by these meta-analyses are either A, poorly done, and the methods are total garbage in some cases, and I don't buy them at all, or B, arguably more disturbingly, the trials themselves don't actually say what the people in the reviews say that they say.

Nick JikomesAnd I can think of very prominent people, some of which I've written about in my substack, they will say in a systematic review, there's no evidence that linoleic acid or omega-6s are pro-inflammatory, they're actually anti-inflammatory, citation. And you go and look at that citation, and it doesn't show that at all. To give people one example, and then I would love to get your sort of commentary on this, to give one example There's clinical trials that are cited to make the claim that omega-6s like linoleic acid are not inflammatory. And when you look at them, what they're actually doing is they're comparing a very, very high linoleic acid seed oil, like sunflower oil, to a much lower linoleic acid seed oil, like canola oil, and showing that things like inflammatory markers are lower in the canola group compared to the sunflower oil group. And then they're saying, well, that means seed oils are not inflammatory and anti-inflammatory because canola oil comes from the seed. But what they're really doing is comparing something with very, very high linoleic acid levels to much lower olive oil-like linoleic acid levels. They seem to be playing a game here, because these people should know better, I think, if they actually understand the underlying biology.

Nick JikomesAnd I've noticed this pattern over and over and over again in this literature in particular. So why do you think this is happening? Are people just being sloppy, or is something else going on?

Floyd "Ski" ChiltonWell, I'm going to dive into the details of why I'm in the minority. I am not the established narrative. I'm not an influencer as well who wants to push seed oils out of the... I'm not either one of those. But many of the biochemists who discovered these molecules, and I kind of say, almost ingest that, I'm the last man standing, not because of anything else that my friends have all retired, the biochemists, or they're dead. And so I'm still kind of standing here. And there's people like Tom Brenna at the University of Texas who we're kind of shoulder to shoulder, but it's us kind of against the world.

Nick JikomesYeah.

Floyd "Ski" ChiltonYeah.

Nick JikomesSo let's just put it this way. Ignore the mainstream narrative for a second. Let's ignore some of the stuff that I just said. Let me just get your perspective on something like omega-6s and inflammation. What is your view on that? And what is the actual evidence behind your view?

Floyd "Ski" ChiltonWe'll get into this in a second, but if in the last 20 years, my lab has a claim to fame, it is showing that based on ancestry, the conversion of linoleic acid to arachidonic acid is dramatically different. And so, when we were first In 1961, and I wasn't around then, but not so far from then, the idea was that if you give 8% of energy or whatever linoleic acid, and only 2% of that energy can go to arachidonic acid, who cares? And so we had a bottleneck. through these de-saturated steps.

Floyd "Ski" ChiltonThey're called fatty acid desaturase one and two, and we had a bottleneck. And so give all you want, maybe you're reducing cholesterol esters, but really who cares?

Nick JikomesRight. So you're saying that the argument at the time was even though linoleic acid, the omega-6 linoleic acid has gone up, the intake has gone up a lot, only a tiny amount of it ends up getting converted to arachidonic acid. So it's not a big deal anyway.

Floyd "Ski" ChiltonThat's right. And if it's having other effects, if it is lowering cholesterol esters, if it's having other effects, then not a problem. Well, you know, 20 years ago or not 20, I think in 2011, we published two papers. And basically what we showed in those two papers was that there was a dramatic difference in the metabolism of linoleic acid in European versus African ancestry populations.

Floyd "Ski" ChiltonAnd again, we didn't do a clinical trial at the time, but when we looked in circulation or in tissues, African ancestry populations had much, much higher levels of arachidone.

Nick JikomesSo what you're saying is, when you look at people, different populations of people, some of them convert linoleic acid onto arachidonic acid much more readily than others. And I actually belong to this group, I know from genomic analysis. And so if arachidonic acid is the source of the other things that we talked about earlier, the pro-inflammatory and pro-thrombotic mediators like prostaglandins, leukotrienes, etc, then you'd have to be careful to sort people based on their genetics because some of them are going to convert way more of that linoleic acid than others.

Floyd "Ski" ChiltonYes, that's the one size fits all. It's not only does it not fit all, but it may be beneficial for one population and profoundly harm another population. And so, I PUFAs and HUFAs are interesting because PUFAs and HUFAs make all of these oxylipins, omega-6, omega-3, they're controlling so much. They're controlling all the endocannabinoids, which is controlling so much.

Floyd "Ski" ChiltonAnd so this little region in chromosome 11 and 12q region that we've studied since 2011 that's responsible for this was a few years back in a Nature communication paper. shown by people who didn't know what a fatty acid was from a protein, just simply looking at chromatin folding, showed that this to be the major morbidity region of the entire human genome.

Nick JikomesWhat does that mean exactly? How did they show that?

Floyd "Ski" ChiltonWell, again, they were looking at chromatin folding, they were looking at this region, they were focusing on this region, and they looked at all the diseases that this region appeared to be responsible for.

Nick JikomesSo, you're saying these were genetics people, they were just looking at the whole genome, they didn't necessarily know about metabolism and metabolite stuff and diet stuff, they're just saying which region of which chromosomes correlates the best with

Floyd "Ski" Chiltonwith cardiovascular cancers with, and again, and once again, they had, you know, I often, well, I said all the time in science, I'd rather be lucky than good. And when we began to study chromosome 11, 12q region, again, I didn't know a genetic variant from a, yeah, again, from a protein. But when we began to study this region, we had no idea that we were sitting on an evolutionary superstar.

Nick JikomesYeah.

Floyd "Ski" ChiltonThis region of the genome was controlling so much and it's controlling so much because it's controlling so much biochemistry and the production of such potent oxylipins omega-6, omega-3, such potent endocannabinoids. And the variants in this region were having huge effect sizes. We were seeing, you know, again, to say it was an evolutionary superstar, I had no appreciation for that. But I know your genetic background and usually if you have effect sizes of four or five percent, you know, your massive celebration.

Floyd "Ski" ChiltonYeah, yeah. Well, we're changing the flux through these pathways by 40 percent.

Nick JikomesForty percent.

Floyd "Ski" ChiltonYes.

Nick JikomesSo what does that mean concretely? Does that mean that if you've got one genotype with respect to this fatty acid metabolism pathway, compared to someone with another genotype, that you could have 40% difference in the levels of these fatty acids?

Floyd "Ski" ChiltonAnd that's what we showed in that 2011 paper. What we showed was that if you were homozygous with, and again, the two variants, we looked evolutionarily with our friends at University of Maryland and our friends at Hopkins, and we showed how and when this derived haplotype arrived, this derived haplotype that are in African ancestry populations. But if you're homozygous for that derived haplotype versus the ancestral haplotype, which we find in native ancestry, native American population, indigenous American populations, and we find it in European ancestry as well, but the difference between homozygous at those two haplotypes, and the haplotypes are 20-some variants in that 11-12q region, there is a 40% difference simply based on that region of the genome.

Floyd "Ski" ChiltonAnd then we saw in that original 2011 paper, there's other regions of the genome that's controlling arachidonic acid formation. And we don't yet know what those regions are. So there was an additional genetic proponent that was pushing that arachidonate. So the idea that 2% of your energy can only go to arachidonate, but who cares becomes, we care a lot.

Nick JikomesRight, right, right. Especially if you have the haplotype that is better at converting that linoleic acid, which again, it's fun to get the data and look at your own genotype and it becomes very consequential as we'll talk about. I've got that genotype. I've got the one that converts very readily to arachidonic acid. And so let's just back up for a sec and explain some of this stuff for people. When we say haplotype, that's like genetic type. So a chunk of one of our chromosomes contains multiple genes for enzymes that process these dietary fats from seed oils and from other things. And there's two major types that are the most common in people.

Nick JikomesAnd different populations have different mixtures of those two types. Some populations, such as those of African ancestry, have type 1. Some populations, like indigenous Americans, have mostly type 2. Some populations have a mix of both type 1 and type 2, and that includes Europeans. I happen to have type 1. and I convert more of that linoleic acid to arachidonic acid. So again, which type you have is very consequential because we're talking about a big effect here. You said this is a big effect, one of the largest effects you see for something like this in terms of genetics.

Floyd "Ski" ChiltonYeah, exactly. I mean, you've done a great job of explaining it. And one of our original paper, after we published a paper in 2012, there was another very consequential paper by Amir and colleagues. And basically, our paper showed the same thing. Our paper showed that this derived Type one, as you call it, appeared in Africa. Now it appeared in Africa. We, with our colleagues at the University of Maryland, believe it appeared around 500,000 years ago. Our 2012 paper says it was driven to fixation in Africa 80,000 years ago.

Floyd "Ski" ChiltonSo, it's driven to fixation in Africa And why? Well, our best hypothesis, our hypothesis goes along with another hypothesis that lipid scientists and geneticists have liked for a long time, is if you were going to keep these big brains and if you were going to make a baby with these big brains, you had to stay around the water and eat shellfish because there simply wasn't enough DHA in any plant source to make a big brain.

Nick JikomesAs you said, so EPA and DHA are omega-3s and so is ALA. We can eat a lot of ALA from plants or enough of it, but it doesn't convert that readily to EPA, DHA. So you would have to eat that EPA and DHA from something like fatty fish, that's what like a fish oil supplement is, in order to get those omega-3s which are really prominent in the human brain.

Floyd "Ski" ChiltonYeah, and so our hypothesis at the time, and it's still our hypothesis, is it was driven to fixation 80,000 years ago because now we can make omega-3s for brain development. We can now, from plant sources. All of a sudden, we're not. And it's interesting because that happened at the same time of the great expansion in Africa. And again, there's a lot of things, and I'm no geneticist, but there were a lot of things happening around that 80,000 year mark that we're going along with increased cognition, great expansion, and again, this would have theoretically allowed for that. Because all of a sudden, you can take ALA from plants and you can convert it to long chain omega-3s for brain development.

Nick JikomesYeah. And sort of the evolutionary story there is really interesting to think about in terms of how this would have happened. But regardless of what the actual evolutionary story is, the brute fact is you've got two major types of fatty acid metabolism with respect to these dietary polyunsaturated fats in humans today. There's version A and version B, or type 1, type 2, whatever you want to call them. And human populations differ systematically in how common those are. So I want to talk a little bit about those differences and what those differences actually mean in terms of outcomes. You've done a variety of studies that speak to that. And there's a variety that we can talk about.

Nick JikomesMaybe one to get us started here is you did a study. I'm just pulling up here on my computer. You did a study of fatty acid desaturase genetic variation and omega-3 deficiency and how it relates to cardiometabolic disease in people with Mexican-American ancestry. So let's talk about that work a little bit. Let's go back to how common each of these two genetic types is for indigenous American populations. Can you remind us of what that looks like?

Floyd "Ski" ChiltonWell, so let me tell the evolution of the type 2, as you're calling it. So type 1 is, I'm a simple country boy. I grew up with a house without a bathroom in the Appalachian Mountains. So I think of plumbing. And these desaturases are plumbing, and it's getting linoleic acid to arachidonic acid. And you've got a big pipe. with type two, as you call it, the derived haplotype. Well, for me, we, in this 2011 paper, we saw that once you get back to the Americas, it's type one, it's the ancestral haplotype.

Floyd "Ski" ChiltonWhat the heck? happened. And again, I'm no geneticist, certainly no evolutionary geneticist. They were saying genetic drift, and that didn't make a whole lot of sense to me, even though I wasn't a geneticist. But there was a critical paper by Thuma Ghali, and it was a science paper, and it was 2015, and it's been built upon, but basically, and built upon by our own lab with our colleagues at the University of Maryland, but basically what it said was, once again, There's one region of the human genome that stands out with cold adaptation. And it's the lead region of the human genome that stands out with cold adaptation. And once again, chromosome 11, 12q, this FADS cluster.

Floyd "Ski" ChiltonSame spot. Same spot. So all of a sudden, now, as you moved up Siberia, you start to, and again, you see it in Northern Europe, you see it in all the places where it's cold, but if you're moving up Siberia and you're hanging out in Beringia 30,000 years ago, all of a sudden you're seeing it completely flip back to this type one.

Nick JikomesSo populations, that came from these colder climates seem to have the genetic type, the chromosome for fatty acid metabolism that is less efficient at making the highly unsaturated fatty acids from the dietary polyunsaturated fatty acids.

Floyd "Ski" ChiltonThat's, and the reason, I mean, they were sitting in 60% fat diets of whale blubber.

Nick JikomesRight, so they would have been eating animal fats that had high levels of these. Of omega-3s. Yes, yes, of things like EPA and DHA and arachidonic acid.

Floyd "Ski" ChiltonSo the evolutionary pressure was off from that perspective, but what the Fumigali paper showed quite beautifully was it was causing the anthropomorphic changes, shorter, more girth, that was necessary. So that was necessary for cold adaptation. And again, we disagree a little bit as to the molecules that were doing that. They were saying, well, this was due to changing growth hormones.

Floyd "Ski" ChiltonAnd again, neither one of us have evidence. I would say that it was due to alterations in the endocannabinoids that was controlling. But they're both controlling size, weight. They're controlling all the things that have been necessary for cold adaptation. It really doesn't matter who's right, because neither one of us can prove. But what did happen unequivocally is you produced a homozygous ancestral or type one haplotype, and now that pipe is really, really small.

Nick JikomesRight. So the pipe going from dietary linoleic acid on the omega-6 side and ALA on the omega-3 side, there's a small pipe from those inputs from the diet to the more highly unsaturated downstream fatty acids.

Floyd "Ski" Chiltonabsent of the biologically active ones.

Nick JikomesAnd basically, the idea here is you didn't need that pipe to be big. You did not need to convert them as much because now you're consuming fatty animal products in northern climates. If people think about Eskimos eating whale blubber and salmon all winter long, this also fits with I had a couple of paleoanthropologists on last year, and they talked about the Clovis peoples, which were basically the precursors to Native Americans living in the last ice age. What did they eat? In their analysis, they showed that they were eating mostly mammoth. So they're eating a high fat, high meat diet that would have been high in arachidonic acid and probably omega-3s like EPA, DHA as well. So it all kind of fits, but at the end of the day, the simple fact is today, the ancestors of all of the people around the world were either one of these types or the other type. And as you mentioned, the difference between them in terms of their fatty acid metabolism is pretty damn big.

Floyd "Ski" ChiltonIt's huge.

Nick JikomesSo now we fast forward to the present day and now we're kind of all living in this modern food environment where we've got a lot of linoleic acid. Some people have got a big pipe connecting the linoleic acid to downstream metabolites. Some people have that smaller pipe because of the other genetic type. So how do we think about that now?

Floyd "Ski" ChiltonWell, so imagine you got the small pipe. I'm going to ask you a question, Nick. Yeah. You got the small pipe. at both your desaturases, your FADS-1 and your FADS-2. You got the small pipe and you feed that pipe a 15 to 1 ratio of linoleic acid to alpha linoleic acid. What do you think you're going to come out of that pipe with if it's small?

Nick JikomesWell, you've got a 15-1 to linoleic to ALA, so you're going to be biased on the omega-6 side. But the pipe is small, so you're going to have less arachidonic acid than someone that has the big pipe. So there might be a bias towards problems or benefits that come from linoleic acid itself as compared to the people with the big pipe who would be more biased to things that come from arachidonic acid and downstream things.

Floyd "Ski" ChiltonDo you think you're going to make much EPA if it's 15 to 1 entering that small pot?

Nick JikomesNo.

Floyd "Ski" ChiltonYou're going to be extremely omega-3 deficient.

Nick JikomesUnless you're eating it in your diet.

Floyd "Ski" ChiltonUnless you're eating it in your diet. One of the, there was a Japanese group, and I'm sorry, I can't pronounce, nor do I remember his name, but one of the predictions after the American Heart Association's 1961 recommendation would be that you would produce an omega-3 deficiency syndrome for this reason. Now again, that group couldn't imagine different size pipes.

Nick JikomesYep.

Floyd "Ski" ChiltonBut now you've got an omega-3 deficiency because you're starting with it. You're still making arachidonate. You're making enough arachidonate.

Nick JikomesYeah, because the linoleic acid intake is so high.

Floyd "Ski" ChiltonIt's so high. You're making enough, but you can't make EPA. Right. And again, EPA is particularly sensitive. Now let's go to what we're finding in Mexico. The last year and a half, so fortunate to be a distinguished professor at Tec de Monterrey and to have access to these huge cohorts. So just to give you an idea, Tec de Monterrey is the most prestigious university in Latin America. We've just spent north of 50 million dollars to sequence 100,000 exomes and another 10,000 whole genomes.

Floyd "Ski" ChiltonAnd so, we now and using a UK Biobank questionnaire, 700 questions, and taking blood from these people and looking at biomarkers, we now have an extraordinary opportunity. It's called the Origen Project, or Origen in English. Now, That's an amazing opportunity. But when I got down there a year and a half ago, they allowed me into their national institutes.

Floyd "Ski" ChiltonAnd there's a national, Dr. Aguilara heads a national institute of medicine and metabolism, medicine, metabolism, and nutrition. And it's equivalent to their NIH. And he had a cohort of 6,200 people. And we had the opportunity to look at these 6,200 people. So we began to look at these 6,200 people and we validated the first thing that's really surprising. And it's really surprising, I guess, to most people, but the thing I find strange is really surprising to Mexicans. But 66% of that population is indigenous American ancestry. So that population is massive.

Floyd "Ski" ChiltonWhile we've screwed up Native American studies here in the US by really horrible things in science, but here we're looking at Latin American populations were indigent because of the bottleneck. Yeah. We're looking at massive populations. Now, the paper that we're about to submit to Nature Metabolism is we've just shown that they're profoundly omega-3 deficient.

Floyd "Ski" ChiltonNow, not only the thing that happens in Mexico, that is a third of the people die of a form of diabetes. that is quite different than the diabetes we see in American.

Nick JikomesSo hold on, before we go on, what you're saying is you're working with this university in Mexico. And in Latin America, in places like Mexico, roughly two thirds of the people have indigenous American ancestry, which means they've got the small pipe genotype for fatty acid metabolism. They're not that good at converting dietary ALA omega-3 into EPA DHA. And therefore, unless they were eating a lot of fatty fish or supplementing, they're going to tend to be omega-3 deficient. And that seems to be what you're actually finding.

Floyd "Ski" ChiltonAnd this is largely the, again, the lower socioeconomic part of the Mexican population. So, not totally, but again, they're not going to go to the store and pay $20 a pound for salmon. And so, this is a particularly, and this may mean nothing, but I've spent 20 years working with non-profits in Africa. When people come into my lab, I tell them, we're not working on science, this is social justice.

Floyd "Ski" ChiltonAnd it really is important that we address these populations because There's just simply not been the diversity to understand the impact of what we're doing to these populations.

Nick JikomesSo I want to say this now so I don't lose track of it throughout the conversation. This is going to connect some other work you've done to this work. But earlier, we talked about how the mainstream narrative is linoleic acid is healthy and not bad. Eating more is better. And you do not share that perspective, neither do I. We just said that people with what we're calling the small pipe genotype, which is very common in people of indigenous American ancestry, they do not convert dietary ALA to longer chain omega-3s like EPA, DHA, and therefore are more prone to omega-3 deficiency. What we haven't mentioned yet, which I think we should also talk about, is that a high linoleic acid diet, a high omega-6 diet, which is what everybody is eating pretty much, actually suppresses tissue levels of EPA, of omega-3s like EPA. So that would mean if we put those two things together, the high linoleic acid modern human diet is going to be really detrimental to these people of indigenous American ancestry that don't readily make EPA and DHA out of ALA.

Floyd "Ski" ChiltonAnd we're about to publish, and I think it's how you found me, we're about to publish a paper, we have the pre-print out there, and this study will never be replicated. I'm just going to say, it was the study from hell. But basically, we took individuals and we put them either on a 10% linoleic acid diet, or a 2.5% energy monolac acid diet.

Nick JikomesSo a 10% diet would be high, and that would actually be what many people in the West are eating today. 2.5% would obviously be much lower, about one quarter of what the typical person is eating today in the West.

Floyd "Ski" ChiltonAnd what made the diet so difficult or the clinical trial so difficult is we had about an 80% dropout rate at 2.5% energy because the population is so used to that taste. And so getting linoleic acid out of the diet took a metabolic kitchen and took a heck of coaxing to get these people to stay on that diet. And again, it was just, like I said, I don't think this study will ever be replicated because I don't think There are very few groups that could be able to stay on this.

Nick JikomesI mean, another way of saying that is basically that linoleic acid is so ubiquitous in the modern food environment and people are so used to it at such high levels that you really have to make a concerted effort to get it under 10% of energy.

Floyd "Ski" ChiltonAnd to get it to 2.5% is next to impossible. So what we've shown in this study, and we're about to publish, and we also have it by genotype, and I won't talk about those studies yet, but what we're about to show is exactly the competition within the pathway. Again, this was in European ancestry populations. who have a diversity of these genotypes, it's about 41% big pipe, it's about 45% little pipe, a middle pipe, and it's about 12% little pipe.

Floyd "Ski" ChiltonSo, most European Americans have the middle pipe.

Nick JikomesOkay, okay.

Floyd "Ski" ChiltonSo, What we showed is in this population, if you go up to 10% of energy, since it's a limited pathway, you dramatically by about 40% reduce ETA, the omega-3 ETA, EPA, and DPA. So at this very high diet, because of the competition within the pathway, you're dramatically reducing the omega-3 side of the pathway because of the 15 to 1 diet that's coming from that pathway.

Nick JikomesAnd so the omega-3s and omega-6s are sort of inextricably linked in this way. If you eat a high linoleic acid diet, which most people today do, 10% of energy, you're actually going to reduce the amount of EPA, which is basically like fish oil fat. On the omega-3 side, you're going to reduce that in your cells.

Floyd "Ski" ChiltonIn your cells. Now, again, we showed in the 2.5% energy linoleic acid, making lots of EPA. The pathway is balanced. The pathway is constrained. We're moving now at about a 3 or 4 to 1 ratio of linoleic acid to alpha linoleic acid, rather than a 15 to 1 ratio. And again, we're making plenty of EPA.

Nick JikomesYeah, yeah, yeah. So you compared, this is European-Americans who are a mixture of the different genetic types. You had half your patients doing 2.5% linoleic acid, which is really low and took a lot of effort to get them to do, compared to high linoleic acid, 10% of energy. The high linoleic acid group is intaking a lot of linoleic acid, omega-6. And that suppresses EPA, omega-3 in their cells. That does not happen for low linoleic acid intake. Another way of saying all that would be that if you reduce linoleic acid intake, you can actually increase tissue levels of the omega-3 EPA.

Floyd "Ski" ChiltonAbsolutely. And so imagine that with European Americans where it's mixed and now go to a population where 66% of the population is indigenous American ancestry and the small pipe is fixed in indigenous American ancestry. So, all of a sudden you've got the small pipe. and you're 15 to one, you're lucky.

Floyd "Ski" ChiltonI mean, when we measure EPA in these people, it is startlingly low.

Nick JikomesVery low.

Floyd "Ski" ChiltonIt's very low. It's almost not measurable.

Nick JikomesWow. So what's funny about this is if you kind of start to put all the things we've started talking about together, the dietary guidelines, the American Heart Association, the NIH, they say, eat a lot of polyunsaturated fats, which in practice is going to mean a lot of omega-6s. That's a high linoleic acid diet. Six to eight percent or more of calories for Americans today are coming from that one molecule. That would mean that in different populations, that's going to have different health effects. And we're telling everyone that it's a one-size-fits-all thing. It's good for everyone. It's heart healthy.

Nick JikomesBut actually, for some people, including most people of Indigenous American ancestry, which is like two-thirds of people of Latin ancestry, that's actually going to make them potentially very omega-3 deficient.

Floyd "Ski" ChiltonYeah, and let me take up for NIH here because NIH has funded me for 38 years.

Nick JikomesYeah.

Floyd "Ski" ChiltonI am incredibly, NIH has allowed me to do this for 38 years and make these observations. So, it's not so much NIH came down on a side. In fact, they have funded me, and I'm so grateful for what NIH has done. But the established narrative, primarily by the epidemiologists, based on the perspective cohort studies, have maintained the narrative, and they're very strong.

Floyd "Ski" ChiltonI mean, my papers are published in lower impact. It's very difficult to go against this narrative. I kind of use a metaphor because I come from, again, a rural background, but it's kind of like my papers are, you know, like I'm driving around in a beat-up you know, VW, and they're in the Maserati. Eventually, you'll find my papers in the beat up VW, but it can be difficult.

Nick JikomesRight. What's sort of funny about that is your papers are often, in my opinion, better controlled in various ways. You're going to great lengths to control the diet in ways that are difficult to control, and many of the other papers don't. You are controlling for things like the haplotypes we're talking about, the genetic types of people, which is a huge confounder in other studies that are out there that are highly cited. We've just gone through this whole conversation talking about how large this genetic effect is on fatty acid metabolism, how much differences there can be between populations of people. There's lots of studies out there that say, oh, we found no effect from changing the polyunsaturated fatty acid content of the diet. They're not controlling at the same level that maybe you are. And they're not controlling for the fact that you've got these different populations, which metabolize these dietary fats in very different ways.

Nick JikomesAnd they're mixing all those people together. And it's no, it's no surprise then that they're actually not picking up some of the signal that you would see if you were to control things this way, and you were to separate people based on their fat metabolism.

Floyd "Ski" ChiltonThat's exactly right. And let me go back to the paper that we're about to submit to Nature Metabolism in Mexico on the 6200 cohort. So, if you can't make EPA, if you can't make EPA, then you can't control You can't control triglyceride biosynthesis because EPA blocks. The one thing EPA does that we all agree on, and I saw you interviewed Bill Harris and Phil Calder.

Floyd "Ski" ChiltonThe one thing we will all agree on is it is great at reducing triglycerides. Now, if you don't have EPA, there are three biochemical steps in your liver that will make triglycerides, because you don't have a break for it. Because what EPA does really, really well is make triglycerides. What EPA also does really well is, if you have it, it'll make more polyunsaturated fatty acids.

Floyd "Ski" ChiltonIf you don't have it, low amounts, it'll make more saturated and unsaturated fatty acids. So, what our hypothesis is and what this paper that we're about to submit says is these populations are hypertriglyceridemic, they're hyperlipidemic in general.

Nick JikomesYeah.

Floyd "Ski" ChiltonAgain, this population, a third of this population dies of this form of diabetes. Wow. So, they're very hyperlipidemic, very hypertriglyceridemic. 49% have fatty liver disease, again, triglycerides in the liver. So all of a sudden, you're looking at this unique form of diabetes that manifests itself much more in that 66% population of indigenous American ancestry. And you're looking at the potential of a mediator that could come out of this pathway that's controlling lipids. in the liver and not only is it controlling lipids, but saturated and monounsaturated triglycerides are much more pathogenic. than triglycerides that contain.

Floyd "Ski" ChiltonSo it's a one-two punch. You're not controlling triglycerides. You're not controlling the lipid composition of those triglycerides. You're producing fatty liver disease and you're getting a population that's dying. It's indigenous American ancestry.

Nick JikomesSo it's simply a fact that in this population, in people of indigenous American ancestry, which is a huge percentage of people in Latin America, they are dying of basically really bad forms of fatty liver disease and diabetes. And you're saying that a recipe for developing that form of illness, that form of disease, is omega-3 deficiency, which is facilitated by a high linoleic acid diet. So if you were such a person, would the advice be, or would something you should want to look into be lowering your omega-6 intake and making sure you're getting decent intake of omega-3s from things like fatty fish?

Floyd "Ski" ChiltonI don't think we can. At this point, we're not going to lower linoleic acid. We're just not going, unless you're a help nut. We're not going to do that.

Nick JikomesSomeone living in, say, a rural or poor region of Latin America who doesn't even know any of this biology that we're talking about, the food environment is so saturated with linoleic acid that it's practically impossible to avoid it.

Floyd "Ski" ChiltonWhat the NIH has me funded for right now is I'm doing a multicenter clinical trial. And the multicenter is between us at the U of A and Georgetown. And we're stratifying by ancestry, African-American, European-American, and we're stratifying by genotype. So we're and then we're feeding either fish oil.

Nick JikomesYeah.

Floyd "Ski" Chiltonwe're feeding high EPA fish oil, or we're feeding, and again, it's a randomized clinical control crossover design, and the placebo is low linoleic acid safflower oil. So, we think, I sent you a paper, I think yesterday, where we saw an 83% reduction in myocardial infarction in re-analyzing the vital trail trial in African-Americans. Again, that's 83% of them have the type 2, as you're calling it, the big pipe. So, they're making lots of arachidonate.

Floyd "Ski" ChiltonThe hypothesis is EPA balances that in that population And now you're seeing profound changes in myocardial infarction. We think the same thing will happen in European ancestry populations in the big pipe people like you.

Nick JikomesYeah.

Floyd "Ski" ChiltonBut again, the effect is being diluted out because of the genetic imbalance, the genetic balance throughout the pipe sizes.

Nick JikomesRight, right, right. So like kind of going back to some of what you said, you've got these two genetic types. Big pipe converts dietary PUFAs into longer chain fatty acids really well. Little pipe genotype doesn't do it so well. And different populations have different frequencies of each of the two types. So in people of European ancestry, basically most white people, you've got a lot of each. It's a pretty good mix of both. You could be type one, you could be type two, you'd have to really check your genetics to know for sure.

Floyd "Ski" ChiltonAnd most of us are heterozygous. So most of us have both or are adults.

Nick JikomesYeah, so you can be type one, you can be type two, in the middle. Most Europeans are in the middle, but you could be either type. Most people of African ancestry are going to tend to be the big pipe version. 83%. Most people of indigenous American ancestry will be the little pipe version.

Floyd "Ski" Chilton66%.

Nick JikomesSo if you take sort of the history of clinical trials done in the United States, in nutrition, predominantly, they're going to have a bias towards European Americans. And so the results could be very different if you were to study different subpopulations, or stratify your population so that you're analyzing different subgroups independently and not mixing everyone together. And so in those studies, and there's a lot of those studies going back decades, they're probably blurring out a lot of biology that's very consequential for human health because they didn't stratify the subpopulations. They just mixed everyone together without regard to these genetic differences.

Floyd "Ski" ChiltonI don't mean to be emotional, but it breaks my heart. I mean, the lack of diversity in those clinical trials breaks my heart.

Nick JikomesYeah. And yet, the guidelines, the mainstream narrative that we've talked about, it really is a one size fits all message that we're telling to everyone. And it just doesn't make sense when you actually look at this biology.

Floyd "Ski" ChiltonThere's another thing I want to bring up for the prospective cohorts that I believe they've gotten wrong. We can move to that in a second or we can continue on the genetics. But I do want to... Okay. So, the way that fatty acids are measured in all of these prospective cohort studies is that they're measured by a technique called GCFID, gas chromatography flame ionization detection. And they're measured in a way that it produces compositional data. So they may measure 30 fatty acids. They'll total the 30 fatty acids.

Floyd "Ski" ChiltonThey'll total them and then each fatty acid is a percent of that total.

Nick JikomesGot it. So it's like a pie chart. You're measuring a bunch of fatty acids and you're talking about them or analyzing them as a percentage of all the fatty acids.

Floyd "Ski" ChiltonSo what happens then is If one fatty acid is going up more than another, let's say that palmitic or the saturators are going up faster than another as total fatty acids increase, then it will make it appear that linoleic acid is going down.

Nick JikomesGot it. Because it might be going down proportionally, but it could still be going up in absolute terms.

Floyd "Ski" ChiltonAnd it is going up in absolute terms.

Nick JikomesYeah. So unpack what this means, because this is important. And even though it's kind of a nerdy detail of the methodology here, why is this important?

Floyd "Ski" ChiltonWell, it's vital because we published this little pedestrian paper in Journal of Nutrition, a British Journal of Nutrition, maybe five, six years ago, that we showed that with lipid biomarkers, the relationships completely flip. as to whether you measure in concentrations or compositional data. So compositional data will, if you look at these biomarker cholesterol, cholesterol esters, they're all going, the more linoleic acid, the better. Those relationships completely flip if you treat fatty acids as concentrations as almost all biomarkers are.

Nick JikomesYeah. Yeah. Yes. So you're saying you interpret the data very differently if you're looking at the relative proportion of things versus measuring the actual literal amount that's inside of someone.

Floyd "Ski" ChiltonThat's right. And now we're about to submit a paper where we've looked at 12 different biomarkers. And 9 of the 12 flip with linoleic acid.

Nick JikomesGive us an example here. What does it mean they flip?

Floyd "Ski" ChiltonWell, so if you're seeing a relationship where higher linoleic acid is reducing what whatever your favorite biomarker is, hemoglobin A1C, CRP, insulin, glucose, LDL, cholesterol, and you're seeing higher on the axis. and you're doing as a percentage of total, linoleic acid is the hero.

Nick JikomesYeah. So let me see if I can translate this for people. What you're basically saying is a lot of studies that have been published historically, which claim to show that linoleic acid is a healthy thing and more of it is better for health, they're showing a positive relationship between linoleic acid and some health outcome. And or they're showing a negative relationship with a bad health outcome. And those studies are using compositional data. So they're measuring the relative linoleic acid level relative to other things. But if you were to measure the actual total absolute amount of linoleic acid, the relationships would be reversed. And something that looked like a healthy relationship when you did it the first way, actually turns out to be an unhealthy relationship when you do it the second way.

Floyd "Ski" ChiltonThat's exactly right. And, you know, it's no one's fault. I mean, unless you're a nerd like me and you were around in the early 1980s and you understood where this technique came from, and how easy it is, and why we use it, and why I can run 300 samples a day through my lab and produce compositional data to the cows come home, you see why it's been used.

Floyd "Ski" ChiltonAnd some people use it even with phospholipids. They'll isolate the phospholipids and still do GCFID in its compositional data. So, we just replicated, we just looked in NHANES, where we had several thousand people, and they had actually analyzed the data by mass spectrometry, negative ion chemical ionization mass spectrometry. And then we took that data, in which we had concentrations, because we had all the deuterated internal standards, we took that data and took it where it was and then converted it to compositional data.

Floyd "Ski" ChiltonAnd again, for linoleic acid, the relationships of nine clinical biomarkers flip.

Nick JikomesYeah. Can you share one example of that?

Floyd "Ski" ChiltonWell, again, cholesterol, cholesterol ester, LDL cholesterol, HDL flips the other way, glucose, insulin, each of these fundamental biomarkers. Now, again, in this study, we don't have all-cause mortality because the size is not large enough. The UK Biobank now has looked at NMR data, and that is concentration data, and there are some limitations. And one of the most recent meta-analyses by an epidemiological group, probably the largest, It's over 300,000 people that show again unequivocally linoleic acid good for you.

Floyd "Ski" ChiltonBut they have a table, and I think it's supplementary table number 13, in which they actually measured linoleic acid by NMR. and actually saw an increase in cardiovascular disease.

Nick JikomesSo basically what you're saying, again, is that a lot of the published literature that associates linoleic acid with healthy outcomes or good biomarker changes is an artifact of the way data is quantified using GCFID as the quantification method.

Floyd "Ski" ChiltonThat's right. And again, I can't say anything about cardiovascular outcomes or all cause mortality. I can't say anything. I can say that the Sydney study that you know about that went up to 12% linoleic acid and they had to stop the study. Admittedly, these were sicker people. Or the Minnesota coronary experiment. Admittedly, sicker people. Those are scary as hell.

Nick JikomesYeah. You're referring to a clinical trial. For those who don't know, he's referring to clinical trials where basically increasing linoleic acid levels killed people more often.

Floyd "Ski" ChiltonAnd in the Sydney trial, again, there's a lot of problems with the Sydney trial. That being said, it is the fact that they had to stop that study so soon, so quickly, at those levels of linoleic acid, even with all of its problems.

Nick JikomesYeah. So for people who don't know, that's the Sydney, as in Sydney, Australia, diet heart study, randomized control trial where linoleic acid was used. These are people who had heart problems. Basically the high linoleic acid group, 12%, which is probably not far off from where a lot of you are eating, they were dying more and they had to stop the trial early because it was so alarmingly big.

Floyd "Ski" ChiltonYeah. And we tend to, you know, again, we tend to forget that. I mean, you know, randomized clinical trials, double-blinded are really difficult in this space. Yeah. We're right in the middle of one and we just finished one. They're really, really difficult. And we're only measuring intermediate molecular phenotypes. We're not to do them in.

Floyd "Ski" ChiltonBut there is a profound difference between a prospective cohort study and a clinical trial. And so it's, again, We, I understand why my friends, and they are my friends, and they're some of the most famous scientists in the world. I understand why the standard narrative is the narrative, and their science supports that.

Nick JikomesWell, on the face of it, it does, but everything that you've told us indicates that those results shouldn't be taken at face value because either the underlying data isn't very good or the way it's quantified with the techniques that are used, it doesn't actually have the relationships it seems to have if you quantify it a different way. That's what you were just telling us.

Floyd "Ski" ChiltonWell, it's time for us. a second look. Those of us who've fought the other side of this have been bulldozed over. I mean, it's been very difficult.

Nick JikomesAs you know, I've had a variety of people on the podcast to talk about the subject, people with different views. I have my own views, which are pretty much in alignment with yours, and I have people on, like Bill Harris recently, and we had some disagreements, and I pushed back somewhat. I could have pushed back a lot more. The criticism I get most from my audience is I don't push back enough. I'm a little bit too, I don't know, too objective or too detached. I just like to allow people to give their perspective. But I did push back a little bit on Bill Harris. It is striking to me that A, we live in a high linoleic acid food environment.

Nick JikomesSoybeans are subsidized. They're a huge crop. We're making a lot of soybean oil and putting it in a lot of foods. And so people are eating a high level of omega-6 linoleic acid. And as your studies showed and others have showed in humans and in animals, high omega-6 linoleic acid suppresses EPA omega-3 levels. That environment is the environment we live in and it's the perfect environment if you wanted to sell cheap food made out of cheap seed oils because that's why they're used. They're cheap. You can get low prices for food if you use seed oils like soybean oil.

Nick JikomesAnd it's the perfect environment if you want to sell a lot of omega-3 fish oil supplements. And both of those are big businesses. It seems like there's a natural symbiosis there between the food industry that wants to use cheap ingredients like seed oils and the supplement industry who wants you to buy supplements to counteract the effects of the diet.

Floyd "Ski" ChiltonWell, because of the methodological things I've mentioned, because of the compositional versus concentration data, I think Bill Harris is a good man. He's a friend of mine. I think Phil Calder is a good man. I don't think the conspiracies kind of go with them. It is interesting that Bill, in his most recent papers, one of the things that happens with this compositional data is you can take compositional data and you can form ratios of that compositional data and its compositional nature removes itself. Yeah, yeah. So one of the things that Bill, and I would probably tickle him a bit of this, is he is now saying one of the best predictors of cardiovascular disease and mortality is the ratio of EPA to arachidon.

Nick JikomesRight, right.

Floyd "Ski" ChiltonI would completely agree with him because the compositional nature of it now disappears because you've put it in the form of a ratio and that disappears.

Nick JikomesRight, right. But to say that another way, the arachidonic acid EPA ratio predicting cardiovascular disease the prediction there, the association is high arachidonic acid, low EPA. In other words, high omega-6, low omega-3, that associates with more heart disease. And high omega-3, lower omega-6, the other way around, that associates with lower heart disease. But again, the mainstream narrative is high omega-6 is heart healthy. So we're talking about the opposite.

Floyd "Ski" ChiltonYeah, yeah. Like I said, I don't, well, it's kind of funny because I say I don't mean to be controversial, but I had a psychology friend who said, no, I beg to differ. But again, we're very careful with our science and the genetics aspect in this region on chromosome 11, the major morbidity region of the entire human genome. Again, more diseases come out of this.

Floyd "Ski" ChiltonWe have to get very serious. Right. This is the poster child.

Nick JikomesYeah.

Floyd "Ski" ChiltonFor predictive nutrition. This is the poster child for precision nutrition. This is the poster child for predictive medicine. Right. This scenario.

Nick JikomesRight.

Floyd "Ski" ChiltonBecause everything else, the effect size, not everything else. Most things, the effect sizes are what they are. But here, we're talking about massive differences in fluxes through these pathways.

Nick JikomesYeah. And massive differences in the frequency of these genotypes in different populations. And, you know, we talked about all that stuff. So, you know, this is a big deal. This matters. To just reiterate one more time for people, most of these studies that have been published out there, most of them, over decades that have to do with linoleic acid, dietary omega-6s, stuff like that. They're not separating people by genotype. They are, in many cases, not actually measuring linoleic acid intake. They're using food frequency questionnaires where people got to remember what they ate in the past year, and they're calculating what they think the nutrition content was. They're not actually measuring it. And A lot of the methods that were used that you talked about, Dr. Chilton, were expressing things as a percentage. This was the compositional data you were referring to.

Nick JikomesThey're using techniques like GCFID to measure the relative amounts of fatty acids rather than the actual absolute amounts. And that methodological difference can completely change the result you get and how you interpret it. most of the literature out there is using that type of data expressed in that way, which is problematic. And it's not sorting people based on these genetically distinct ways of metabolizing fatty acids. And we've built up an entire public health messaging apparatus around it.

Floyd "Ski" ChiltonWell, and again, the tragedy is not having the diversity. in these trials. I mean, the tragedy is having such a Eurocentric, I mean, such a Eurocentric view and analysis of this problem.

Nick JikomesYeah. Well, I want to, like, with that in mind, I want to ask you about the study you did looking at fatty acid desaturase genetic variants in African Americans So this is a population that has mostly the big pipe version of the genotype. As I mentioned a couple of times, that's actually the one that I have. So it's relevant to me in that sense. Something like 40 some odd percent of European Americans have the genotype, but more than 80% of African Americans or people with African ancestry have it. What was that study and what did you find?

Floyd "Ski" ChiltonWell, so we recently, well, recently, 2024, reanalyzed the vital study. And again, the vital study was published by Dr. Mattson in the New England Journal of Medicine. And it was 26,000 people or so. And it really put the, you know, it put the kind of the end to omega-3s.

Floyd "Ski" ChiltonIn the last line of the abstract, shows no evidence in cardiovascular disease or cancer. So, huge 26,000 people study. Now, again, to their credit, they noticed and put in the supplementary, New England Journal of Madison allowed them to put in the supplementary, that this seemed to be working or it seemed to be efficacious in African-Americans, the omega-3s. So, we took the 5,100 African Americans out of the study.

Floyd "Ski" ChiltonWe could get complete data with 3,766 of these people. We then took the 3,766 and we had around 18,000 European Americans left and we could perfectly balance these called optimal propensity matching. So, again, the covariance can be dramatically different in the populations, but we found 3,766 whites out of all of those whites that we could perfectly match with the 3,766 blacks.

Nick JikomesWell, so in other words, they did this big trial, they gave a bunch of people tens of thousands of mega three supplements, didn't find any good effects that were worth mentioning and said, Oh, I guess they don't work. What you actually did is you took out a subset of African Americans and a subset of European ancestry people. These two groups are gonna differ on average in the big pipe versus little pipe fatty acid metabolism genotype. And so you took out those and you match them in terms of their covariance. So age, lifestyle factors, other things that could be- Smoking, diabetes, heart disease, cardiovascular.

Floyd "Ski" ChiltonSo we perfectly match them with over 20 different covariance.

Nick JikomesAnd so you compared them, and then what did you see?

Floyd "Ski" ChiltonThen we did three machine learning algorithms to resimulate the clinical trial. And so what the data showed, and I think it's why NIH funded the current study, is the data showed that those African-Americans on omega-3s had an 83% reduction in myocardial infarction, heart attacks.

Nick JikomesOver 80% reduction in heart attacks in the group that got omega-3 supplementation.

Floyd "Ski" ChiltonExactly. And in a decision tree, it was the first thing to come off the decision tree. This was a five and a half year study. is the first thing to come off the decision tree for the African-Americans, did not show up in a machine learning decision tree in the whites, first thing to come off to prevent heart attacks. So an 83% reduction in heart events in the African-Americans, and it had no effect in the whites. But again, the whites, we believe, the distribution of genetics is hiding the fact. We think the hypothesis is Omega-3s will work with you because you have a pipe.

Nick JikomesRight, you would just need to have that specific genotype level data to do that. And obviously you don't have that for all of the people in these studies. But again, it's a lesson in, it looks like nothing interesting is happening when you treat everyone as one homogenous blob. But when you sub-sample, when you sub-group people based on ancestry or based on genotype, you were able to do with ancestry in this case, you actually start to see big differences that are very consequential for people. Like the effect that you mentioned was not tiny. 83% reduction in myocardial infarction is That's a big result.

Floyd "Ski" ChiltonWell, and it brings to the point, again, NIH has funded this trial, this, again, African-Americans, European-Americans stratified by genotype. The Aranti Foundation in Mexico, which is the largest foundation funding biomedical research, just gave our group, me, $380,000 in Mexico to do this in a Mexican population. We think cardiometabolic disease and cardiovascular disease are going to look different. We think, again, we'll measure the impact of this clinical trial, not on cardiovascular disease because it's not large enough.

Floyd "Ski" ChiltonWhat we want to do with the NIH trial is say, you know what, if we're going to spend a lot of money, we're going to do this again, let's choose the populations that it'll be efficacious on. Yeah. In the trial that we're doing, though, in Mexico that was just funded by the Erante Foundation, again, we're now looking at that hyperlipidemic form of diabetes in this population. And again, the patient population there is not that they've already progressed to fatty liver disease, but they're in a pre-stage.

Nick JikomesYeah.

Floyd "Ski" ChiltonAnd the quest, wouldn't it be wonderful Wouldn't it be incredible if you could simply give EPA to people who are dying of this hyperlipidemic form of diabetes and shut down that triglyceride biosynthesis in those individuals to prevent that form of diabetes or at least prevent that form in a significant portion of the population?

Nick JikomesYeah.

Floyd "Ski" ChiltonI mean, it's a simple solution. I mean, yeah, we're not giving statins.

Nick JikomesYeah, you don't have to come up with a new drug that you do clinical trials to test. You don't have to reinvent the wheel on anything. This is already something that exists.

Floyd "Ski" ChiltonYeah.

Nick JikomesWow, so what's interesting about some of the stuff that you've said is, so you just talked about that study where you were studying the Mexican study, where you were studying populations of people with indigenous American ancestry. This is a little pipe fatty acid converting population, and they seem to be prone to omega-3 deficiency. And that would imply that, you know, getting more omega-3s through supplementation or through food would help. We then also mentioned some of the research you did in African-American populations.

Nick JikomesThat's a big pipe population. It's the other genetic type. And they had a benefit from omega-3 supplementation as well. But in this case, it was myocardial infarction. It was heart health stuff rather than liver health stuff.

Floyd "Ski" ChiltonExactly. And you're making an important distinction here because the disease subtypes are quite different here.

Nick JikomesSo it does not seem to be the case that high omega-6, low omega-3 is good for some people and bad for others. It seems to be that high omega-6 and low omega-3 is bad in some ways for some populations and maybe bad in other ways or more so in other ways for other populations. So given everything that we've talked about, including your work and everything you've seen in the field, your knowledge of all the methods and all of the details on the history of this stuff, Given the fact that people today are eating six, eight, 10% of their energy coming from linoleic acid, a high omega-6 diet in absolute terms and relative to omega-3s, is there any health benefit to eating that level of omega-6s for anyone?

Nick JikomesAnd is there any risk to lowering it in your view?

Floyd "Ski" ChiltonThe answer is I Let me be careful here. The answer is we don't know for sure, but I strongly, strongly, I think that not I'm right, we're right, I think that some profoundly important things have been overlooked here. It has led us into a difficult health position, especially for populations that are already being devastated by unfair health treatments.

Nick JikomesOne more thing I want to ask you about in the time we have left, you know, we've talked about the controversies and the problems with many of the studies in this literature, generally speaking, nutrition epidemiology, nutrition science, the clinical research, the whole umbrella of nutrition science. A lot of these studies and a lot of people don't know this. I didn't know this until I started doing this podcast and I started reading this stuff. A lot of the studies that are out there, They don't actually measure food intake. They don't actually measure nutrient intake. They guess what those things are by calculating numbers after they ask people to remember what they ate. So literally in a lot of these big studies that have lots of citations, I just want to emphasize this for people. It's literally like this.

Nick JikomesThe way they're measuring intake and nutrition is they're having someone come in and a researcher saying, tell me how much of each of these 60 foods you ate in the last year. Now, think about that for a second. When people are on trial for murder and there's a life and death consequence, we know that eyewitness testimony is not very reliable. And that's when people were at the scene and they saw something with their own two eyes. A lot of the nutrition science is asking people to remember what they ate in the last year and then calculating and assuming what the nutrition content should have been for what people remembered eating and everything that they analyze is based on that. That's the data. What do you think about this literature and the quality of that data? Is that valid data to be analyzing and should we be taking these studies seriously or are these food frequency questionnaires not very reliable and we shouldn't be looking at these studies that much?

Floyd "Ski" ChiltonWell, I think there's more sophisticated ones. We use 24-hour recalls because we have to start somewhere. So when we're entering these people into clinical trials, we have to start somewhere. This is difficult. It's a difficult science. I think for what we're talking about today, I think we can be fairly comfortable that everyone is, you know, we always in our clinical trials, we have an amount of linoleic acid diet by gene interaction and you need to know the exposure. Well, in our studies, it really doesn't make a whole lot of difference because if you're 7%, 8%, that gene variation the exposure is not going, as long as you're up that high. I think we can be, as far as this science is concerned, your point is incredibly well taken.

Floyd "Ski" ChiltonBut I think we can all agree that we're somewhere in the 6 to 9% linoleic acid. And that is, whether it's 8 to 1 or 20 to 1, be confident that that's an imbalance. And again, I'm not putting down what you're saying at all. There are more sophisticated methodologies than food frequency questionnaires, and we don't use them.

Floyd "Ski" ChiltonWe use 24-hour recalls. And so, there are more sophisticated, but inherent in in this is a great deal, to your point, of uncertainty.

Nick JikomesYeah. One thing I like about the types of studies you tend to do is you're not merely using something like a 24-hour recall, which is already better than a food frequency questionnaire where you're asking someone to remember a year's worth of feeding, which is ridiculous in my opinion. So 24-hour recall is better. But on top of that, what you guys do is you'll actually measure serum levels and tissue levels of specific fatty acids. So you do have an actual measurement of absolute levels of this stuff. And it's not just a pure guesstimate. Exactly.

Floyd "Ski" ChiltonBut also knowing that that's going to be impacted by the genetics of the person. the moment they eat that linoleic acid or alpha linoleic acid, what you're going to see in circulation is going to be impacted by the desaturases in the liver and the fat tissue.

Nick JikomesYeah, yeah, yeah. And as we mentioned, but I just want to emphasize it again because it's so important. These are big effect sizes we're talking about. The genotype differences in terms of how how your body will convert these dietary fats into other things are very large. These are some of the largest sort of effects that we see, you know, in human genetics.

Floyd "Ski" ChiltonAnd, you know, folks that want to look at that, our original 2011 BMC Genetics, Floyd Chilton, go look at figure three. to look at figure three of that, look at the amount of arachidonate, look at the DGLA to arachidonate ratio, which is the conversion across that delta 5 desaturase, what you're going to see is massive frequency differences in the genotypes between African and European Americans. And you're going to see massive differences between those genotypes. And then you're going to see additional differences that are not accounted for in the FADS cluster that we don't know where it's coming from, but there's still an African ancestry population.

Floyd "Ski" ChiltonSo that figure three, that figure three will, if you want to see the flux through that pathway, go look at that figure three.

Nick JikomesHow has your career and your knowledge in this whole area influenced your own relationship to diet and food? Do you try and minimize or at least not eat too much dietary linoleic acid? Do you try and really get good sources of omega-3s from whole foods? What is your personal approach to these dietary polyunsaturated fats?

Floyd "Ski" ChiltonYeah, my personal approach is even with my knowledge, if you get linoleic acid down from 8% to 6%, I don't think it matters a whole lot.

Nick JikomesYou're saying that even 6% is too high.

Floyd "Ski" ChiltonIs too high. So I think, for me, they use these highly concentrated and not to advertise for anyone, but formamide is providing us the ingredients for our clinical trials. that they're capsules with, you know, two, you get 1200 milligrams EPA, DHA, and two thirds of that is EPA relative to DHA. That is my balancing act.

Floyd "Ski" ChiltonYou know, I too have your genotype. So that is my balancing act as well. And again, I eat a Mediterranean diet. A lot of olive oil, a lot of manna, mufas. Mediterranean diet, a bit ketogenic, really emphasizing fish, and then fish oil supplements.

Nick JikomesAny final thoughts you want to leave people with or anything you want to reiterate on our discussion today, including things we talked about that you want to say in different words or just hammer home one more time, or things maybe like that you're doing in your lab that we can look forward to in the near future?

Floyd "Ski" ChiltonWell, I think we will continue. There's a reason at my age I haven't retired. This is a calling. It's not, this is social justice. It's why I've spent 20 years with nonprofits in Africa. This, we have to get this right. And it's one thing, it's one thing if we're making recommendations that are not helpful. It's another thing if we're making recommendations that are harmful.

Floyd "Ski" ChiltonAnd it's even worse if we're making recommendations that are harmful, that are creating horrible health disparities. And so we've got to be careful. We've got to be less confident. We've got to rethink, I'm very encouraged that there are now methods such as NMR that can measure linoleic acid concentrations and not just compositional data.

Floyd "Ski" ChiltonWe can, if we keep measuring the compositional data, We're going to keep coming up with the same false conclusions, the same answer. And I won't even call them false. I'm not because I haven't seen all cause mortality. I'm being very careful. But we're going to keep coming up with those conclusions and we can keep throwing rocks at each other over the fence. And their rocks are much bigger than mine, but in terms of who they are and where they are, but we just have to do this right. We have to understand what's at stake here. We have to be a little less confident and a little more open to discussion and conversations.

Nick JikomesAnd as we discussed, know, you've spent your career sort of in disagreement to various degrees with the dominant narrative with respect to dietary polyunsaturated fats and the things that we talked about. There's a famous quote, which I'll paraphrase from Max Planck, I think, a physicist. And, you know, he famously said something like science progresses one funeral at a time. And, you know, you mentioned earlier that you're sort of, Literally, people who thought your way retired and died off, and the dominant narrative became dominant because the people who believed it either stuck around longer, or they had louder voices, or whatever.

Nick JikomesWhat do you think about that quote in terms of how science progresses and what actually determines what becomes the so-called consensus view? Is it always a matter of the consensus view is built from the best science and winning out? Or do other factors play into this that don't necessarily have to do with the best evidence determining what becomes the dominant view?

Floyd "Ski" ChiltonYeah. I was speaking to my partner last night about the importance of pedigrees in science and pedigrees from different groups. And while my pedigree is strong, I'm not coming out of the big places, especially right now. There are example after example, and I'm not putting myself in the same category, but there's example after example of scientists who's had an alternative view who have been crushed.

Floyd "Ski" ChiltonAnd I'm not saying I've been crushed. I'm so grateful to NIH. I'm so grateful that I've been able to do this. But there, Max Planck, you can go to Einstein. And again, I don't put myself in those categories, but you can one right after another. And there's a huge legacy. of having an alternative view that turns out to be right. Now, maybe the scientist doesn't find that out in their lifetime, but there's a huge legacy of that.

Floyd "Ski" ChiltonI don't need to be right. I just simply don't want people to suffer because we're so sure we're right.

Nick JikomesWell, I think that's a great place to end it. Dr. Chilton, thank you very much for your time. I've been reading your work for a while and I've been trying for a little while to get you on and I'm glad I finally did. Yeah, thank you very much. I really appreciate it and I look forward to talking to you again in a year or two when some more your work comes out.

Floyd "Ski" ChiltonWell, Nick, this has been so much fun and you blow me away with how much you know this field. What a great interview and what a great way to be able to discuss this. So I honor you and I honor your podcast.

Nick JikomesHey everyone, a great way to support my efforts is to visit my support page at mindandmatter.substack.com. A link to that page is in the episode description, or you can search for it on the Substack page itself. The support page has an up-to-date list of my affiliate partners. These are companies I work with, and if you buy those products through those links or using the discount codes provided, those will get you a great deal on a variety of products related to optimizing physical, metabolic, or mental health and vitality. These are all products I use myself, and some of them are directly related to podcast episodes or formulated by Mind & Matter guests. For example, there's a great product called Keto Citra formulated by a kidney biologist who is on episode number 186. It contains the ketone body BHB together with several minerals in a precise ratio formulated with kidney health in mind. There are also links to products like physical technology devices to track your metabolic health, digital applications to help you find and learn about food and consumer products, and more.

Nick JikomesOne product I use every day is the AquaTrue water filter. I recommend this to everyone because it gets everything out of your drinking water, heavy metals, microbes, endocrine disruptors, microplastics, you name it. Other charcoal or gravity-based filters that a lot of people use don't get everything out, they just get some of the stuff out. So I really like the AquaTrue product. You can look for a link to my affiliate partners on my support page or directly in the episode description to this episode, or you can go to mindandmatter.substack.com to find it there.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Seed Oils, Omega-3s & Lessons From 93 Years of Life | Artemis Simopoulos | 313

    Nov 17, 20261 hr 35 minAudio

    Send us Fan Mail At 93, Artemis Simopoulos explains why oils once used in paint now dominate the food supply, how a high omega-6 intake slows the making of EPA and DHA, and why cholesterol-lowering corn oil did not...

    Credit the people on this episode

  2. Tendons, Collagen, mTOR & Exercise Adaptation | Keith Baar | Episode 312

    Nov 10, 20262 hrAudio

    Send us Fan Mail Keith Baar explains why tendons stop adapting after 10 minutes of loading, why long low-load holds beat fast reps for connective tissue, and how vitamin C, collagen, caffeine and mTOR shape training....

    Credit the people on this episode

  3. GDF15, Morning Sickness & Mitochondrial Stress | Stephen O'Rahilly | Episode 311

    Nov 3, 20261 hr 29 minAudio

    Send us Fan Mail Dr. Stephen O'Rahilly explains GDF15, a stress hormone that makes us feel sick and eat less, and why morning sickness, and its severe form hyperemesis gravidarum (HG), comes from GDF15 made by the...

    Credit the people on this episode

  4. Psilocybin vs. SSRIs for Depression, Emotional Blunting & How Psychedelics Work | Robin Carhart-Harris | 310

    Oct 26, 20261 hr 56 minAudio

    Send us Fan Mail Robin Carhart-Harris explains why his trial of psilocybin therapy vs. the SSRI escitalopram for depression missed one primary measure but favored psilocybin on almost everything else, and why SSRIs can...

    Credit the people on this episode

  5. This Animal Survives 18 Minutes Without Oxygen | Gary Lewin | 309

    Oct 12, 20261 hr 40 minAudio

    Send us Fan Mail Nick talks with Prof. Gary Lewin (Max Delbrück Center, Berlin) about naked mole-rats, which in lab tests survived 18 minutes in pure nitrogen by shutting down brain activity, keeping the heart beating,...

    Credit the people on this episode